Quest for the right Drug
בטנזול טבליות BETNESOL TABLETS (BETAMETHASONE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The frequencies of undesirable effects are ranked according to the following: Very common (≥1/10) Common (≥1/100, <1/10) Uncommon (≥1/1,000, <1/100) Rare (≥1/10,000, <1/1,000) Very rare (<1/10,000) Not known (frequency cannot be estimated from the available data) Table 1: Undesirable effects that occurred with systemic betamethasone System organ Undesirable classes and effects Endocrine disorders Not known Cushing’s syndrome, inactivation or atrophy of the adrenal cortex Gastrointestinal disorders Not known Abdominal discomfort, Ulcus ventriculi or duodeni (risk of perforation), ulcerative oesophagitis, bleeding, pancreatitis; risk of perforation with pre-existing Colitis ulcerosa Infections and infestations Not known Increased risk of susceptibility to infections; masking of infections; exacerbation of latent infections (mycosis, virus infections, bacterial infections, protozoa infection, candidosis, Blood and lymphatic system disorders Not known Leucocytosis. Immune system disorders Not known Decreased immune response; allergic reaction, anaphylactic reactions including shock. Eye disorders Not known Cataract, glaucoma, exophthalmos, blurred vision (see also section Cardiac disorders Not known Myocardial rupture after recent infarct Metabolism and nutritional disorders Not known decreased carbohydrate tolerance, diabetes mellitus, oedema, osteoporosis, sodium retention with formation of oedema, increased potassium excretion, catabolic effect on protein metabolism (negative nitrogen balance), Musculoskeletal and connective tissue and bone disorders Not known Muscle atrophy and weakness, myopathy, growth retardation in children, osteoporosis, osteonecrosis (Femur and Capitulum humeri), tendon rupture Psychiatric disorders Not known Mental disorders, psychosis, personality changes, confusion. Nervous system disorders Not known Insomnia, vertigo, headache, Pseudotumor cerebri (particularly in children), manifestation of latent epilepsy und increase of seizures in manifest epilepsy, increased nervousness and Reproductive system and breast disorders Not known Disturbance of sexual hormone secretion (menstrual disorders, Skin and subcutaneous tissue disorders Not known Striae rubrae, atrophy, telangiec tasia, Vascular disorders Not known Hypertension, thrombosis, vasculitis Respiratory, thoracic and mediastinal disorders Not known Hiccups Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Endocrine disorders, hypercalcemia associated with cancer, rheumatic disorders, collagen diseases, acute rheumatic carditis, dermatological diseases, severe allergic conditions, ophthalmic diseases, respiratory diseases, hematological disorders, neoplastic diseases, gastrointestinal diseases, nephrotic syndrome, tuberculous meningitis, trichinosis, multiple sclerosis
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף